Importantly, it has been experimentally demonstrated that monomeric Aβ42 supplementation can rescue behavioral deficits both in PSEN1/PSEN2 conditional double knockout AD mice and in APP/PSEN/Tau triple transgenic AD mice, an effect mediated through binding of Aβ42 to α7‐nAChR [130]. This evidence concerns the gene MAPT and Alzheimer disease.